© 2025 MergersCorp M&A International.
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
生物技术企业,拥有 2500 多例临床治疗的良好安全记录。 公司设计、制造和销售亲和血液过滤产品。 这是一种高度创新的新型血液过滤装置,它采用已获专利的专有生物仿生技术,可快速清除血液感染患者体内的细菌、真菌、细菌毒素、病毒、促炎细胞因子和败血症介质。
投资呼吁
全球受败血症影响的患者数以百万计,败血症市场每年约有 3000 万例病例。
这项技术的其他应用还包括:作为生物武器攻击(COVID)的应对措施、PDAC 癌症、防止在诊断、血库和生物处理中使用 ECMO 和心肺旁路时产生的副作用。
到 2028 年底,该公司的估值将达到 400 亿美元,仅为追踪净利润的 10 倍。
发展机遇
强有力的管理
毛利率>85
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
This website is operated by MergersUS Inc a US Corporation with registered office at
报错: 未找到这个表单
报错: 未找到这个表单
报错: 未找到这个表单
报错: 未找到这个表单
报错: 未找到这个表单
描述
生物技术企业,拥有 2500 多例临床治疗的良好安全记录。 公司设计、制造和销售亲和血液过滤产品。 这是一种高度创新的新型血液过滤装置,它采用已获专利的专有生物仿生技术,可快速清除血液感染患者体内的细菌、真菌、细菌毒素、病毒、促炎细胞因子和败血症介质。
投资呼吁
全球受败血症影响的患者数以百万计,败血症市场每年约有 3000 万例病例。
这项技术的其他应用还包括:作为生物武器攻击(COVID)的应对措施、PDAC 癌症、防止在诊断、血库和生物处理中使用 ECMO 和心肺旁路时产生的副作用。
到 2028 年底,该公司的估值将达到 400 亿美元,仅为追踪净利润的 10 倍。
发展机遇
强有力的管理
毛利率>85
Basic Details
Target Price:
待定
Business ID:
L#20240619
Country
美国
详情
Similar Businesses
Published on 23 2 月, 2024 在 7:26 下午. 更新 21 1 月, 2025 在 9:02 上午
大麻农场(非精神活性大麻或休闲大麻)
$13,000,000
Medical Businesses, 制药
20年历史的制药南美品牌
$11,500,000
制药, 制药, 制造业, 制造业
历史制药制造业务
$1,050,000,000
制药
拥有 40 年历史的制药企业
$40,000,000
制药, 制药, 制造业, 制造业
拥有 40 年历史的中东和北非制药公司
$45,000,000
制药, 制药
获得许可的瑞士药品批发业务
待定
制药
PREVIOUS PROPERTY
家禽和鸡蛋生产业务
NEXT PROPERTY
3x 28MW + 31MW + 31MW 风力发电厂 管道